GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Results] 65 weeks on 15mg, full numbers, ask me anything boring — 31 comments in the full submission. View in context.
675
c/tirzepatide·submitted 1 months ago by u/slow_logbook_ftw

[Results] 65 weeks on 15mg, full numbers, ask me anything boring

Resultsbranch of 16 comments

Check-in as promised in the title: 65 weeks on 15mg, full numbers, ask me anything boring. The relevant figures are 65 weeks and 15mg, and they come from the same log I have kept the whole time. The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two…

Read the full submission and all 31 comments →

This branch

16 comments, started 1 months ago
u/alcohol_aversion36 points·1 months ago

The step schedule question, answered properly, because it comes up weekly.

The label sets a minimum interval of four weeks between increases. That is a floor on how fast you may go, and it exists because tolerability, not efficacy, is what limits most people. There is nothing in the pharmacology that says you must increase at four weeks, or at eight, or ever.

What decides it in practice is whether the effect you want is still there. If appetite is quiet and the trend is going the right way, the dose is doing its job. If both have genuinely gone flat for six weeks or more, that is a conversation worth having with someone who knows your history.

replysharereportpermalink
u/yusuf_ramos28 points·1 months ago

6kg over 25 weeks, never went past 10mg, and reflux stayed mild the whole way. Posting because the loud threads are all 15mg.

replysharereportpermalink
u/fatima_wojcik-26 points·1 months ago

2.5 is the starter dose and it is not meant to be the dose that works

replysharereportpermalink
u/ewan_marchand8 points·1 months ago

the trials titrated on a calendar, real people titrate on symptoms

replysharereportpermalink
u/copay_card_cc2 points·1 months ago

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

replysharereportpermalink
load more comments (11) →

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.